{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:29:32Z","timestamp":1793053772863,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12094-016-1590-1","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T07:05:31Z","timestamp":1480316731000},"page":"1243-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["SEOM Clinical Guideline for bone metastases from solid tumours (2016)"],"prefix":"10.1007","volume":"18","author":[{"given":"C.","family":"Gr\u00e1valos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00c1.","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Virizuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cassinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"1590_CR1","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","volume":"16","author":"JJ Body","year":"1998","unstructured":"Body JJ, Bartl R, Burchardt P, Delmas PD, Diel IJ, Fleisch H, et al. Current use of bisphosphonates in oncology. J Clin Oncol. 1998;16:3890\u20139.","journal-title":"J Clin Oncol"},{"key":"1590_CR2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastases: the \u201cseed and soil\u201d hypothesis revisited. Nat Rev Cancer. 2003;3:453\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1590_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2015","unstructured":"Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2015;27:165\u201376.","journal-title":"Cancer Treat Rev"},{"key":"1590_CR4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2106\/00004623-198668050-00017","volume":"68","author":"JH Healey","year":"1986","unstructured":"Healey JH, Turnbull AD, Miedema B, Lane JM. Acrometastases. A study of twenty-nine patients with osseous involvement of the hands and feet. J Bone Joint Surg Am. 1986;68:743\u20136.","journal-title":"J Bone Joint Surg Am"},{"key":"1590_CR5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12094-013-1077-2","volume":"16","author":"I Dur\u00e1n","year":"2014","unstructured":"Dur\u00e1n I, Garz\u00f3n C, S\u00e1nchez A, Garc\u00eda-Carbonero I, P\u00e9rez-Gracia JL, Segu\u00ed-Palmer MA, et al. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. Clin Transl Oncol. 2014;16:322\u20139.","journal-title":"Clin Transl Oncol"},{"key":"1590_CR6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Rodman","year":"2004","unstructured":"Rodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364.","journal-title":"N Engl J Med"},{"key":"1590_CR7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen A\u00d6, Jacobsen JB, N\u00f8rgaard M, Fryzek JP, S\u00f8rensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007). Breast Cancer Res Treat. 2011;129:495\u2013503.","journal-title":"Breast Cancer Res Treat"},{"key":"1590_CR8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10555-006-9024-0","volume":"25","author":"LB Tanko","year":"2006","unstructured":"Tanko LB, Karsdal MA, Christiansen C, Leeming DJ. Biochemical approach to the detection and monitoring of metastatic bone disease: what do we know and what questions need answers? Cancer Metastasis Rev. 2006;25:659\u201368.","journal-title":"Cancer Metastasis Rev"},{"key":"1590_CR9","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z","volume":"88","author":"LM Demers","year":"2000","unstructured":"Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88:2919\u201326.","journal-title":"Cancer"},{"key":"1590_CR10","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate and zoledronic acid. J Clin Oncol. 2005;23:4925\u201335.","journal-title":"J Clin Oncol"},{"key":"1590_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-005-9094-7","volume":"97","author":"M Clemens","year":"2006","unstructured":"Clemens M, Cole D, Gainford M. Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat. 2006;97:81\u201390.","journal-title":"Breast Cancer Res Treat"},{"key":"1590_CR12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urology.2003.09.044","volume":"63","author":"R Petrioli","year":"2004","unstructured":"Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, et al. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology. 2004;63:321\u20136.","journal-title":"Urology."},{"key":"1590_CR13","doi-asserted-by":"crossref","first-page":"10115","DOI":"10.3390\/molecules190710115","volume":"19","author":"M Croset","year":"2014","unstructured":"Croset M, Santini D, Iuliani M, Fioramonti M, Zoccoli A, Vincenzi B, et al. MicroRNAs and bone metastasis: a new challenge. Molecules. 2014;19:10115\u201328.","journal-title":"Molecules"},{"key":"1590_CR14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bone.2012.10.033","volume":"52","author":"K Valencia","year":"2013","unstructured":"Valencia K, Mart\u00edn-Fern\u00e1ndez M, Zandueta C, Ormaz\u00e1bal C, Mart\u00ednez-Canarias S, Bandr\u00e9s E, et al. miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. Bone. 2013;52:532\u20139.","journal-title":"Bone"},{"key":"1590_CR15","doi-asserted-by":"crossref","unstructured":"Blake GM, Park-Holohan S-J, Cook GJR, Fogelman I. Quantitative studies of bone with the use of 18 F-fluoride and 99\u00a0m Tc-methylene diphosphonate. In: Seminars in nuclear medicine. Elsevier; 2001. p. 28\u201349.","DOI":"10.1053\/snuc.2001.18742"},{"issue":"5","key":"1590_CR16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12149-012-0595-2","volume":"26","author":"T Katayama","year":"2012","unstructured":"Katayama T, Kubota K, Machida Y, Toriihara A, Shibuya H. Evaluation of sequential FDG-PET\/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumour markers. Ann Nucl Med. 2012;26(5):426\u201335.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"1590_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1148\/radiol.2373041358","volume":"238","author":"D Utsunomiya","year":"2006","unstructured":"Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT\/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238(1):264\u201371.","journal-title":"Radiology"},{"key":"1590_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00259-013-2532-6","volume":"41","author":"H Palmedo","year":"2014","unstructured":"Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, T\u00fcrler A, et al. Whole-body SPECT\/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nuclear Med Mol Imaging. 2014;41:59\u201367.","journal-title":"Eur J Nuclear Med Mol Imaging."},{"issue":"2","key":"1590_CR19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","volume":"22","author":"J Rong","year":"2013","unstructured":"Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S. Comparison of 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):86\u201391.","journal-title":"A meta-analysis. Surg Oncol."},{"issue":"7","key":"1590_CR20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF02985050","volume":"19","author":"K Abe","year":"2005","unstructured":"Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG-PET with 99mTc-HMDP scntigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005;19(7):573\u20139.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"1590_CR21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1148\/radiol.10092469","volume":"257","author":"C Reischauer","year":"2010","unstructured":"Reischauer C, Froehlich JM, Koh D-M, Graf N, Padevit C, John H, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps\u2013initial observations. Radiology. 2010;257(2):523\u201331.","journal-title":"Radiology"},{"issue":"2","key":"1590_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"1590_CR23","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.2967\/jnumed.115.157867","volume":"57","author":"GJ Cook","year":"2016","unstructured":"Cook GJ, Azad GK, Goh V. Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med. 2016;57(Suppl 1):27S\u201333S.","journal-title":"J Nucl Med"},{"issue":"4","key":"1590_CR24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/1097-0142(19830815)52:4<610::AID-CNCR2820520406>3.0.CO;2-5","volume":"52","author":"RC Coombes","year":"1983","unstructured":"Coombes RC, Dady P, Parsons C, McCready VR, Ford HT, Gazet JC, et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 1983;52(4):610\u20134.","journal-title":"Cancer"},{"issue":"11","key":"1590_CR25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-006-0141-3","volume":"33","author":"O Israel","year":"2006","unstructured":"Israel O, Goldberg A, Nachtigal A, Militianu D, Bar-Shalom R, Keidar Z, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mole Imaging. 2006;33(11):1280\u20134.","journal-title":"Eur J Nucl Med Mole Imaging."},{"issue":"Suppl 1","key":"1590_CR26","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumours. J Nucl Med. 2009;50(Suppl 1):122S\u201350S.","journal-title":"J Nucl Med"},{"issue":"7","key":"1590_CR27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0009-9260(98)80168-2","volume":"53","author":"AL Brown","year":"1998","unstructured":"Brown AL, Middleton G, MacVicar AD, Husband JES. T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol. 1998;53(7):493\u2013501.","journal-title":"Clin Radiol"},{"key":"1590_CR28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","volume":"6","author":"C Decroisette","year":"2011","unstructured":"Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 2011;6:576\u201382.","journal-title":"J Thorac Oncol."},{"issue":"9","key":"1590_CR29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u201345.","journal-title":"Mayo Clin Proc"},{"key":"1590_CR30","doi-asserted-by":"crossref","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;(Suppl 3); 25:iii124\u2013iii137.","DOI":"10.1093\/annonc\/mdu103"},{"key":"1590_CR31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"SL Rosen","year":"2004","unstructured":"Rosen SL, Gordon D, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36\u201343.","journal-title":"Cancer"},{"key":"1590_CR32","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314\u201321.","journal-title":"J Clin Oncol"},{"key":"1590_CR33","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/JCO.2013.49.4757","volume":"32","author":"GN Hortobayi","year":"2014","unstructured":"Hortobayi GN, Lipton A, Chew HC, Gradishar WJ, Sauter N, Mohanlal R, et al. Efficacy and safety of continued zoledronic acid every 4\u00a0weeks versus every 12\u00a0weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. J Clin Oncol. 2014;32:5s (suppl; abstr LBA9500).","journal-title":"J Clin Oncol."},{"key":"1590_CR34","doi-asserted-by":"crossref","unstructured":"Himelstein AL, Qin R, Novotny PJ, Seisler DK, Khatcheressian JL, Roberts JD, et al. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol. 2015;33 (suppl; abstr 9501).","DOI":"10.1200\/jco.2015.33.15_suppl.9501"},{"issue":"15","key":"1590_CR35","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"1590_CR36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10555-013-9480-2","volume":"33","author":"DL Suzman","year":"2014","unstructured":"Suzman DL, Boikos SA, Carducci MA. Bone-targeting agents in prostate cancer. Cancer Metastasis Rev. 2014;33(2\u20133):619\u201328.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"1590_CR37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879\u201382.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1590_CR38","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014;32(11):1143\u201350.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1590_CR39","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedian LS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung cancer and other solid tumours: a randomized, phase III trial, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613\u201321.","journal-title":"Cancer"},{"issue":"35","key":"1590_CR40","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1590_CR41","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1590_CR42","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol"},{"key":"1590_CR43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322.","journal-title":"Lancet"},{"key":"1590_CR44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12094-012-0832-0","volume":"14","author":"J Cassinello","year":"2012","unstructured":"Cassinello J, Gonz\u00e1lez del Alba A, Rivera F, Holgado E. SEOM guidelines for the treatment of bone metastases from solid tumours. Clin Transl Oncol. 2012;14:505\u201311.","journal-title":"Clin Transl Oncol."},{"issue":"12","key":"1590_CR45","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823\u20139.","journal-title":"J Thorac Oncol."},{"issue":"8","key":"1590_CR46","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1590_CR47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadjan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data of patients with solid tumours. Support Care Cancer. 2014;22(3):679\u201387.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1590_CR48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2012.04.001","volume":"323","author":"J Goyal","year":"2012","unstructured":"Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 2012;323(2):135\u201346.","journal-title":"Cancer Lett"},{"issue":"8","key":"1590_CR49","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","volume":"27","author":"VJ Lewington","year":"1991","unstructured":"Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954\u20138.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1590_CR50","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","volume":"63","author":"O Sartor","year":"2004","unstructured":"Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940\u20135.","journal-title":"Urology."},{"issue":"12","key":"1590_CR51","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1590_CR52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"7","key":"1590_CR53","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738\u201346.","journal-title":"Lancet Oncol."},{"issue":"1","key":"1590_CR54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijrobp.2008.10.044","volume":"75","author":"A Hird","year":"2009","unstructured":"Hird A, Chow E, Zhang L, Wong R, Wu J, Sinclair E, et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. Int J Radiat Oncol Biol Phys. 2009;75(1):193\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1590_CR55","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.ijrobp.2008.12.084","volume":"75","author":"A Fairchild","year":"2009","unstructured":"Fairchild A, Barnes E, Ghosh S, Ben-Josef E, Roos D, Hartsell W, et al. International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys. 2009;75(5):1501\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1590_CR56","first-page":"231","volume":"20","author":"S Hayashi","year":"2002","unstructured":"Hayashi S, Hoshi H, Iida T. Reirradiation with local field radiotherapy for painful bone metastases. Radiat Med. 2002;20(5):231\u20136.","journal-title":"Radiat Med"},{"issue":"2","key":"1590_CR57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijrobp.2003.10.006","volume":"59","author":"Y Linden van der","year":"2004","unstructured":"van der Linden Y, Lok J, Steenland E, Martijn H, van Houwelingen H, Marijnen CA, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004;59(2):528\u201337.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1590_CR58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0167-8140(92)90338-U","volume":"23","author":"P Hoskin","year":"1992","unstructured":"Hoskin P, Price P, Eason D, Regan J, Austin D, Palmer S, et al. A prospective randomized trial of 4\u00a0Gy or 8\u00a0Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992;23:74\u20138.","journal-title":"Radiother Oncol"},{"issue":"7","key":"1590_CR59","first-page":"782","volume":"22","author":"P Jhaveri","year":"2008","unstructured":"Jhaveri P, Teh BS, Bloch C, Amato R, Butler EB, Paulino AC. Stereotactic body radiotherapy in the management of painful bone metastases. Oncology. 2008;22(7):782\u20138.","journal-title":"Oncology."},{"issue":"15","key":"1590_CR60","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1002\/cncr.25918","volume":"117","author":"AK Garg","year":"2011","unstructured":"Garg AK, Wang XS, Shiu AS, Allen P, Yang J, McAleer MF, et al. Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: the University of Texas MD Anderson Cancer Center experience. Cancer. 2011;117(15):3509\u201316.","journal-title":"Cancer"},{"issue":"3","key":"1590_CR61","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ijrobp.2008.09.020","volume":"74","author":"A Sahgal","year":"2011","unstructured":"Sahgal A, Ames C, Chou D, Ma L, Huang K, Xu W, et al. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys. 2011;74(3):723\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1590_CR62","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2010.11.026","volume":"79","author":"S Lutz","year":"2011","unstructured":"Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79:965\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1590_CR63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","volume":"366","author":"RA Patchell","year":"2005","unstructured":"Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366:643\u20138.","journal-title":"Lancet"},{"issue":"1","key":"1590_CR64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0019-5413.143915","volume":"49","author":"MG Agarwal","year":"2015","unstructured":"Agarwal MG, Nayak P. Management of skeletal metastases: an orthopaedic surgeon\u00b4s guide. Indian J Orthop. 2015;49(1):83\u2013100.","journal-title":"Indian J Orthop."},{"key":"1590_CR65","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8:R13.","journal-title":"Breast Cancer Res"},{"key":"1590_CR66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","volume":"19","author":"T Saarto","year":"2001","unstructured":"Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19:10\u20137.","journal-title":"J Clin Oncol"},{"key":"1590_CR67","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98\u2013101.","journal-title":"Cancer Metastasis Rev"},{"key":"1590_CR68","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, De Boer R, Eidtmann H, Liombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398\u2013405.","journal-title":"Ann Oncol"},{"key":"1590_CR69","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12:631\u201341.","journal-title":"Lancet Oncol."},{"key":"1590_CR70","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365:1396\u2013405.","journal-title":"N Engl J Med"},{"key":"1590_CR71","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)61032-7","volume":"386","author":"R Coleman","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353\u201361.","journal-title":"Lancet."},{"key":"1590_CR72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432\u201344.","journal-title":"Lancet."},{"key":"1590_CR73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature14492","volume":"522","author":"TR Cox","year":"2015","unstructured":"Cox TR, Rumney RMH, Schoof EM, Perryman L, H\u00f8ye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522:106\u201310.","journal-title":"Nature"},{"key":"1590_CR74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433\u201343.","journal-title":"Lancet"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-016-1590-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-016-1590-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-016-1590-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:51:36Z","timestamp":1568595096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-016-1590-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s12094-016-1590-1","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}